This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia
Leukemia Open Access 23 February 2023
-
Epigenetic silencing of UBXN8 contributes to leukemogenesis in t(8;21) acute myeloid leukemia
Experimental & Molecular Medicine Open Access 17 December 2021
-
MicroRNA let-7b downregulates AML1-ETO oncogene expression in t(8;21) AML by targeting its 3′UTR
Experimental Hematology & Oncology Open Access 02 February 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Downing JR . The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. Br J Haematol 1999; 106: 296–308.
Mulloy JC, Cammenga J, Berguido FJ, Wu K, Zhou P, Comenzo RL et al. Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood 2003; 102: 4369–4376.
Heidenreich O, Krauter J, Riehle H, Hadwiger P, John M, Heil G et al. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood 2003; 101: 3157–3163.
Martinez N, Drescher B, Riehle H, Cullmann C, Vornlocher HP, Ganser A et al. The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells. BMC Cancer 2004; 4: 44.
McCormack E, Bruserud O, Gjertsen BT . Review: genetic models of acute myeloid leukaemia. Oncogene, advance online publication 11 February 2008: DOI 10.1038/onc.2008.1016.
Pearce DJ, Taussig D, Zibara K, Smith LL, Ridler CM, Preudhomme C et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 2006; 107: 1166–1173.
Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti JC, Lanzavecchia A et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004; 304: 104–107.
Tallman MS, Hakimian D, Shaw JM, Lissner GS, Russell EJ, Variakojis D . Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. J Clin Oncol 1993; 11: 690–697.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Soria, N., Tussiwand, R., Ziegler, P. et al. Transient depletion of RUNX1/RUNX1T1 by RNA interference delays tumour formation in vivo. Leukemia 23, 188–190 (2009). https://doi.org/10.1038/leu.2008.157
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.157
This article is cited by
-
Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia
Leukemia (2023)
-
MicroRNA let-7b downregulates AML1-ETO oncogene expression in t(8;21) AML by targeting its 3′UTR
Experimental Hematology & Oncology (2021)
-
Epigenetic silencing of UBXN8 contributes to leukemogenesis in t(8;21) acute myeloid leukemia
Experimental & Molecular Medicine (2021)
-
Destabilization of AETFC through C/EBPα-mediated repression of LYL1 contributes to t(8;21) leukemic cell differentiation
Leukemia (2019)
-
The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype
Leukemia (2016)